Outcomes-Based Financing as a Tool to Curb AMR
Antimicrobial resistance (AMR) is one of the most pressing public health challenges of the 21st century, particularly in LMICs, where economic and social factors exacerbate the misuse of antibiotics. At the 2024 Clinton Global Initiative Annual Meeting, PATH, in partnership with the Alliance, Pfizer, and the governments of Tanzania and Senegal announced a Commitment to Action to tackle AMR through an innovative outcomes-based financing mechanism. This approach aims to strengthen antimicrobial stewardship by addressing behavioral and market incentives that drive the overuse of antibiotics, fostering sustainable solutions to curb AMR in resource-limited settings.
Outcomes-Based Financing: A Novel Tool in the Fight Against AMR | PATH and Partners Share New Research and Model to Drive Responsible Antibiotic Use
MAY 15, 2025
At a recent Clinton Global Initiative (CGI) Deeper Dive Session, PATH — together with Pfizer, the Bay Area Global Health Alliance, and Social Finance International — shared early-phase research findings aimed at understanding the drivers of antibiotic misuse and presented an innovative financing design approach to incentivize the correct use of antibiotics. The session aimed to raise awareness and engage potential partners around a next-phase pilot to test outcomes-based financing (OBF) as a new tool to drive more sustainable and effective stewardship.
Tackling AMR with Outcomes-Based Financing: Findings from Tanzania and Senegal
MARCH 12, 2025
On February 25, Neha Agarwal, senior director of strategy at PATH and Alliance board vice chair, led a session for Stanford Mussallem Center for Biodesign’s Innovation and Health Equity Series. She discussed how outcomes-based financing (OBF) can be leveraged to tackle antimicrobial resistance (AMR). Her talk, which provided a first look at data from a year-long study in Tanzania and Senegal, emphasized how innovative financing mechanisms could reshape global health strategies.
PATH, Pfizer, and the Bay Area Global Health Alliance Partner to Combat Antimicrobial Resistance in Senegal and Tanzania Using an Outcomes-Based Financing Mechanism
OCTOBER 4, 2024
During the Clinton Global Initiative (CGI) 2024 Annual Meeting, PATH, in partnership with the Bay Area Global Health Alliance and Pfizer, announced a Commitment to Action: Outcomes-Based Financing as a Tool to Curb AMR in LMICs. This commitment aims to combat antimicrobial resistance (AMR) and incentivize antimicrobial stewardship (AMS) through an innovative outcomes-based financing mechanism.
Outcomes-Based Financing as a Tool to Curb AMR in LMICs
SEPTEMBER 24, 2025
In 2024, PATH committed to develop and pilot an outcomes-based financing (OBF) mechanism to incentivize antimicrobial stewardship (AMS) efforts specifically in low- and middle-income countries (LMIC) to support and improve human health. This mechanism aims to address the underlying infrastructure and health systems gaps in order to achieve a comprehensive stewardship approach. It also focuses on incentivizing health provider networks in LMICs to pilot innovative business models and service delivery approaches that prevent, undo, or counteract the economic and social incentives driving the overuse or incorrect use of antibiotics.
Health Equity, AI, and Partnership: 2023 Annual Meeting Highlights
JUNE 9, 2023
“The ambitious agenda [of Africa CDC’s Digital Transformation Strategy] over such a huge continent cannot be achieved unless every available resource is harnessed. And that can only be done through cross-collaboration partnerships,” said Africa CDC’s Chief Digital Health Adviser, Jean Philbert Nsengimana, at the Bay Area Global Health Alliance annual meeting on June 6. Attending were more than 125 members and guests, both online and in person at UCSF.